B and T lymphocyte attenuator (BTLA) and PD-1 pathway dual blockade promotes antitumor immune responses by reversing CD8+ T-cell exhaustion in non-small cell lung cancer
Our results show that BTLA and PD-1 cooperatively inhibit the activity of CD8<sup>+</sup> T cells and are associated with resistance to PD-1/PD-L1 pathway blockade in NSCLC patients. Anti-BTLA blockade enhances the antitumor efficacy of anti-PD-L1 therapy. Dual BTLA and PD-1/PD-L1 blockade should be further explored to elicit potent antitumor CD8<sup>+</sup> T-cell responses in NSCLC patients.
Authors
- Chuanyong Mu (ORCID: https://orcid.org/0000-0002-1370-6542)
- Lei Wei (ORCID: https://orcid.org/0000-0002-1881-8666)
- Jingyu Mao
- Zeyi Liu (ORCID: https://orcid.org/0000-0003-2528-6909)
- Yuanyuan Zeng (ORCID: https://orcid.org/0000-0002-2260-4468)
- Yang Zhang (ORCID: https://orcid.org/0000-0002-3209-5118)
- Yang Yang (ORCID: https://orcid.org/0000-0003-0728-167X)
- Jianan Huang (ORCID: https://orcid.org/0000-0002-5371-5670)
- Lirong Gao (ORCID: https://orcid.org/0000-0002-9477-1206)
- Meiqin Su
- Qiu‐Xia Qu (ORCID: https://orcid.org/0000-0002-2836-2092)
- Cheng Chen (ORCID: https://orcid.org/0000-0003-0177-2814)
- Dan Shen
Institutions
- Soochow University (CN)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-05-20
- DOI
- https://doi.org/10.3389/fimmu.2025.1553042
- Citations
- 7
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 7.32